SELLAS Life Sciences Group, Inc. (SLS)Healthcare | Biotechnology | New York, United States | NasdaqCM
11.88 USD
-0.53
(-4.271%) ⇩
(Oct. 14, 2026, 4 p.m.
EDT)
After hours: 11.66 -0.22 (-0.215%) ⇩ (Oct. 14, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:12 a.m. EDT
The immediate outlook is driven by a binary event: the upcoming leukemia trial readout. The market has priced in a dramatic re-rating, with analysts targeting $32.50 despite the stock trading near $11.65. This optimism is mirrored in the options chain, where traders are stacking calls at $20 and $30 strikes while hedging downside risk with put walls at $5. However, the fundamental reality remains starkly different from the speculative fervor. The company is burning cash, reporting negative free cash flow and negative returns on equity, with no dividend to cushion the blow. While the short-term momentum is robust due to the pending catalyst, the long-term investment case is neutral at best; the business lacks the sustained profitability and balance sheet strength required for a permanent 'buy' rating. Investors here are betting on a successful trial, not a proven business model. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.175756 |
| AutoETS | 0.205086 |
| AutoARIMA | 0.205093 |
| MSTL | 0.233223 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.59 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.368 |
| Excess Kurtosis | -0.91 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.535 |
| Market Cap | 2,399,115,008 |
| Forward P/E | -118.80 |
| Beta | 2.57 |
| Website | https://sellaslifesciences.com |
As of Oct. 10, 2026, 8:12 a.m. EDT: Speculators are aggressively positioning for a massive upside move, evidenced by heavy call volume and open interest at strikes ranging from $17.50 to $30.00 across multiple expirations. There is a distinct 'call wall' forming at $20-$30, suggesting a collective bet on a catalyst-driven rally. Conversely, put writers are establishing significant defensive walls at lower strikes ($4.00-$6.00), indicating a fear of a sharp drop if the anticipated clinical trial data fails to meet expectations. The implied volatility skew shows elevated premiums for deep out-of-the-money calls, reflecting high uncertainty and asymmetric reward potential.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.449541 |
| Address1 | 7 Times Square |
| Address2 | Suite 2503 |
| All Time High | 718,500.0 |
| All Time Low | 0.5 |
| Ask | 15.09 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 4,522,300 |
| Average Daily Volume3 Month | 6,443,921 |
| Average Volume | 6,443,921 |
| Average Volume10Days | 4,522,300 |
| Beta | 2.571 |
| Bid | 9.02 |
| Bid Size | 2 |
| Board Risk | 5 |
| Book Value | 0.682 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.88 |
| Current Ratio | 18.827 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 12.4399 |
| Day Low | 11.71 |
| Debt To Equity | 0.535 |
| Display Name | SELLAS Life Sciences |
| Dividend Date | 1,573,171,200 |
| Dividend Yield | 0.0 |
| Earnings Timestamp End | 1,794,427,200 |
| Earnings Timestamp Start | 1,794,427,200 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 2,261,509,120 |
| Eps Current Year | -0.2 |
| Eps Forward | -0.1 |
| Eps Trailing Twelve Months | -0.21 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.4654 |
| Fifty Day Average Change | -0.5853996 |
| Fifty Day Average Change Percent | -0.046961963 |
| Fifty Two Week Change Percent | 444.9541 |
| Fifty Two Week High | 15.88 |
| Fifty Two Week High Change | -4.0 |
| Fifty Two Week High Change Percent | -0.25188917 |
| Fifty Two Week Low | 1.39 |
| Fifty Two Week Low Change | 10.49 |
| Fifty Two Week Low Change Percent | 7.5467625 |
| Fifty Two Week Range | 1.39 - 15.88 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,205,328,600,000 |
| Float Shares | 201,148,023 |
| Forward Eps | -0.1 |
| Forward P E | -118.8 |
| Free Cashflow | -16,378,375 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Fullday Change | -0.60999966 |
| Fullday Change Percent | -4.915388 |
| Fullday Price | 11.88 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00922 |
| Held Percent Institutions | 0.36943 |
| Implied Shares Outstanding | 201,945,709 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,573,171,200 |
| Last Split Factor | 1:50 |
| Long Business Summary | SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. |
| Long Name | SELLAS Life Sciences Group, Inc. |
| Market | us_market |
| Market Cap | 2,399,115,008 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_262231850 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -32,461,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,322,375,653 |
| Number Of Analyst Opinions | 2 |
| Open | 12.19 |
| Operating Cashflow | -28,423,000 |
| Operating Margins | 0.0 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 646 200 5278 |
| Post Market Change | -0.21549988 |
| Post Market Change Percent | -1.813972 |
| Post Market Price | 11.6645 |
| Post Market Time | 1,792,022,343 |
| Previous Close | 12.41 |
| Price Eps Current Year | -59.4 |
| Price Hint | 2 |
| Price To Book | 17.419355 |
| Profit Margins | 0.0 |
| Quick Ratio | 18.278 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.53 |
| Regular Market Change Percent | -4.27075 |
| Regular Market Day High | 12.4399 |
| Regular Market Day Low | 11.71 |
| Regular Market Day Range | 11.71 - 12.4399 |
| Regular Market Open | 12.19 |
| Regular Market Previous Close | 12.41 |
| Regular Market Price | 11.88 |
| Regular Market Time | 1,792,008,000 |
| Regular Market Volume | 4,725,416 |
| Return On Assets | -0.23299 |
| Return On Equity | -0.39633998 |
| Sand P52 Week Change | 0.1570785 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 201,945,709 |
| Shares Percent Shares Out | 0.273 |
| Shares Short | 55,128,974 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 57,926,912 |
| Short Name | SELLAS Life Sciences Group, Inc |
| Short Percent Of Float | 0.2741 |
| Short Ratio | 8.57 |
| Source Interval | 15 |
| State | NY |
| Symbol | SLS |
| Target High Price | 35.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 32.5 |
| Target Median Price | 32.5 |
| Total Cash | 138,343,008 |
| Total Cash Per Share | 0.685 |
| Total Debt | 737,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.14775 |
| Two Hundred Day Average Change | 3.7322502 |
| Two Hundred Day Average Change Percent | 0.4580713 |
| Type Disp | Equity |
| Volume | 4,725,416 |
| Website | https://sellaslifesciences.com |
| Zip | 10,036 |